INSANE: 4 | Rare Historical Photos

The UK’s pharma deal was vital – but the GSK boss is right about US dominance

It would be absurd to claim the UK has suddenly become a life-sciences leader thanks to the new pricing and tariffs pact

The Guardian - UK · Dec 11, 2025

US is the best place for drug companies to invest, says boss of London-based GSK

Emma Walmsley’s praise for US pharmaceutical market piles pressure on UK government

The Guardian - UK · Dec 11, 2025

Boss of drugs giant GSK declares US best place to invest

Dame Emma Walmsley said the US was still leading the way for new drugs and vaccines.

Evening Standard · Dec 11, 2025

Stocks mixed and pound dips amid Budget tax hints

The FTSE 100 Index closed up 13.59 points at 9,714.96.

Evening Standard · Nov 4, 2025

We need clarity on big pharma’s tax breaks

Letters: Pharmaceutical giants like GSK should be more transparent about the generous tax breaks they get from the UK government, says Mike Lewis

The Guardian - UK · Nov 3, 2025

UK must reform drug pricing to become life sciences superpower, says GSK boss

Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved

The Guardian - UK · Oct 29, 2025

GSK boosted by cancer and HIV drugs as Emma Walmsley bows out

Shares in the company rose on Wednesday morning as a result, lifting to their highest level for more than a year.

Evening Standard · Oct 29, 2025

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.

Benzinga · Oct 29, 2025

FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep

On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.

Benzinga · Oct 24, 2025

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD-GRN).

Benzinga · Oct 22, 2025